Yahoo! FinanceFinance Home - My Yahoo - Yahoo! - Help 

Sunday, December 20, 2009, 11:14AM ET - U.S. Markets Closed. Dow Up 0.20% Nasdaq Up 1.45%
Neurologix Inc. (NRGX.OB)On Dec 18: 0.50   0.00 (0.00%)  
MORE ON NRGX.OB
Quotes
Charts
News & Info
Company
HereProfile
Analyst Coverage
Ownership
Financials

ProfileGet Profile for:
Neurologix Inc.
One Bridge Plaza
Fort Lee, NJ 07024
United States - Map
Phone: 201-592-6451
Fax: 203-661-1331
Web Site: http://www.neurologix.net

DETAILS 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Manufacturers - Major
Full Time Employees:11

BUSINESS SUMMARY 
Neurologix, Inc., a development stage company, engages in the discovery and development of therapeutic treatments for disorders of the brain and central nervous system. The company’s treatments are designed as alternatives to conventional surgical and pharmacological treatments. It primarily focuses on gene therapy for treating Parkinson’s disease, a neurodegenerative disorder; and epilepsy, a group of diseases associated with recurrent seizures, which is caused by periodic episodes of repetitive, abnormal electrochemical disturbance in the central nervous system, beginning in the brain. The company also focuses on the development of gene transfers for the treatment of neurodegenerative and metabolic disorders, including Huntington’s disease, depression, and metabolic syndrome or genetically-based obesity. Neurologix, Inc. was founded in 1999 and is based in Fort Lee, New Jersey.
Key Statistics

COMPANY WEBSITES 
  • Home Page
  • Search Yahoo! for:
    More on Neurologix Inc.


    CORPORATE GOVERNANCE 
    Neurologix Inc.'s Corporate Governance Quotient (CGQ®) as of 1-Dec-09 is better than 23.4% of CGQ Universe companies and 10.3% of Pharmaceuticals, Biotechnology & Life Sciences companies.
    Brought to you by Institutional Shareholder Services.

    KEY EXECUTIVES 
     PayExercised
    Mr. John E. Mordock , 63
    Chief Exec. Officer, Pres
    $ 275.00KN/A
    Mr. Marc L. Panoff , 38
    Chief Financial Officer, Sec. and Treasurer
    $ 203.00KN/A
    Dr. Christine V. Sapan Ph.D., 61
    Chief Devel. Officer and Exec. VP
    $ 264.00KN/A
    Dr. Matthew J. During M.D., D.Sc,
    Founder and Member of Scientific Advisory Board
    N/A N/A
    Dollar amounts are as of 31-Dec-08 and compensation values are for the last fiscal year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of options exercised during the fiscal year.
    View Insiders


    Add to My Portfolio Add to Portfolio    Set Alert Set Alert    Email to a Friend Email to a Friend
    Get Profile for Another Symbol: Symbol Lookup
    Annual ReportsSector Analysis